Drug Trial Radar · NCT03432286
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Last checked: Nov 20, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
533
Actual
Start
Mar 14, 2018
Primary completion
Nov 14, 2025
Study completion Nov 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Feb 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Conditions
- Episodic Migraine
Interventions
GalcanezumabDrug
Administered SQ
PlaceboDrug
Administered SQ
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in the Number of Monthly Migraine Headache DaysTime frame: Baseline, 3 Months
Locations
73 sites in 10 countries. Site status is shown where the registry gives one.
Rehabilitation & Neurological Services
Huntsville, Alabama
21st Century Neurology, a Division of Xenoscience, Inc.
Phoenix, Arizona
Phoenix Children's Hospital
Phoenix, Arizona
Center for Neurosciences
Tucson, Arizona
Miller Children's & Women's Hospital Long Beach
Long Beach, California
Wr-McCr, Llc
San Diego, California
Children's Hospital Colorado
Aurora, Colorado
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
Jacksonville, Florida
University of Miami Don Suffer Clinical Research Building
Miami, Florida
Ezy Medical Research
Miami Lakes, Florida
Clinical Neuroscience Solutions
Orlando, Florida
Avanza Medical Research Center
Pensacola, Florida
USF Health
Tampa, Florida
Premiere Research Institute at Palm Beach Neurology
West Palm Beach, Florida
Clinical Integrative Research Center of Atlanta, LLC
Atlanta, Georgia
Meridian Clinical Research, LLC
Savannah, Georgia
Medical Research Partners
Ammon, Idaho
Elite Clinical Trials
Blackfoot, Idaho
Northwest Clinical Trials
Boise, Idaho
Inpatient Pharmacy
Hoffman Estates, Illinois
University of Kentucky Chandler Medical Center
Lexington, Kentucky
Pharmasite Research, Inc.
Baltimore, Maryland
Boston Clinical Trials
Boston, Massachusetts
MedVadis Research Corporation
Waltham, Massachusetts
Minneapolis Clinic of Neurology - Burnsville Office
Burnsville, Minnesota
Children Mercy Pediatric Clinical Research Unit
Kansas City, Missouri
Dent Neurologic Institute
Amherst, New York
Cohen Children's Northwell Health Physician Partners - Pediatric Neurology
New Hyde Park, New York
Velocity Clinical Research at Raleigh Neurology
Raleigh, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Providence Health & Services
Portland, Oregon
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Office 18
Pittsburgh, Pennsylvania
Velocity Clinical Research, Providence
East Greenwich, Rhode Island
Tribe Clinical Research, LLC
Greenville, South Carolina
Pain and Headache Centers of Texas
Houston, Texas
Northwest Clinical Research Center
Bellevue, Washington
Seattle Children's Hospital
Seattle, Washington
Sanos Clinic - Nordjylland
Aalborg, Denmark
Herlev and Gentofte Hospital
Copenhagen, Denmark
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.